Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$9.56 0.2  2.2%

Last Trade - 30/07/21

Sector
Healthcare
Size
Small Cap
Market Cap £242.2m
Enterprise Value £34.4m
Revenue £n/a
Position in Universe 4135th / 7015

Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial

Mon 17th May, 2021 12:45pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210517:nGNX6fwV4T&default-theme=true


Company to host conference call on Wednesday, May 19, 2021 at 6:00 PM ET

CAMBRIDGE, Mass. and NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- Black Diamond
Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company
pioneering the discovery and development of small molecule, MasterKey
therapies, today announced that it will host a webcast presentation on
Wednesday, May 19, 2021 at 6:00 PM ET to discuss pharmacokinetic, safety, and
preliminary efficacy data from the Phase 1 dose-escalation portion of the
MasterKey-01 trial of BDTX-189 in patients with advanced solid tumors, which
will also be presented at the 2021 American Society of Clinical Oncology
(ASCO) Annual Meeting, taking place June 4-8, 2021.

Conference Call and Webcast Event

A live webcast presentation will be available on the News & Events section of
the Black Diamond website at www.blackdiamondtherapeutics.com. To access the
presentation, please dial 833-730-3983 (United States) or 720-405-2158
(international) and reference the conference ID 1979666. A replay of the
webcast will be available on the Black Diamond website following the
presentation.

Abstract Details:

Title: Safety and Preliminary Efficacy from the Phase 1 Portion of
MasterKey-01: A First-in-Human Dose-Escalation Study to Determine the
Recommended Phase 2 Dose (RP2D), Pharmacokinetics (PK), and Preliminary
Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB mutations, in
Patients with Advanced Solid Malignancies
Session Type: Poster Session
Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor
Biology
Date and Time: Friday, June 4, 2021 at 9:00 AM ET
Abstract ID: 3086

Title: Clinical pharmacokinetics of BDTX-189, an inhibitor of allosteric ErbB
mutations, in patients with advanced solid malignancies in MasterKey-01 study
Session Type: Poster Session
Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor
Biology
Date and Time: Friday, June 4, 2021 at 9:00 AM ET
Abstract ID: 3097

Full abstracts will be published online at 5:00 PM ET on May 19, 2021 on the
ASCO website at www.asco.org.

About BDTX-189
BDTX-189 is an orally available, irreversible, and ATP competitive small
molecule inhibitor that is designed to block the function of a family of
oncogenic epidermal growth factor receptor (EGFR) and ErbB-2 (epidermal growth
factor receptor 2  HER2 ) proteins across a range of tumor types. BDTX-189 is
designed as a MasterKey inhibitor targeting a family of previously undrugged
and functionally similar oncogenic mutations in a tumor-agnostic manner. These
mutations include extracellular domain allosteric mutations of HER2, as well
as EGFR and HER2 kinase domain Exon 20 insertions, and additional activating
oncogenic drivers of ErbB. The ErbB receptors are a group of receptor tyrosine
kinases involved in key cellular functions, including cell growth and
survival. BDTX-189 is also designed to spare normal, or wild-type, EGFR, which
we believe has the potential to improve upon the toxicity profiles of current
ErbB kinase inhibitors. Currently, there are no medicines approved by the U.S.
Food and Drug Administration (FDA) to target all of these oncogenic mutations
with a single therapy.

BDTX-189 is currently being evaluated in a Phase 1/2 clinical trial
(MasterKey-01) in adult patients with advanced solid tumors expressing a range
of alterations of ErbB receptors, including oncogenic MasterKey mutations,
HER2-WT amplification, HER3 mutation, EGFR exon 19 deletion, and L858R
mutation who have no standard therapy available or for whom standard therapy
is considered unsuitable or intolerable. In July 2020, the FDA granted Fast
Track designation to BDTX-189 for the treatment of adult patients with solid
tumors harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20
insertion mutation who have progressed following prior treatment and who have
no satisfactory treatment options.

About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering
the discovery of small molecule, MasterKey therapies. Black Diamond targets
undrugged mutations in patients with genetically defined cancers. Black
Diamond is built upon a deep understanding of cancer genetics, protein
structure and function, and medicinal chemistry. The Company’s proprietary
technology platform and drug discovery engine,
Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black
Diamond to analyze population-level genetic sequencing data to identify
oncogenic mutations that promote cancer across tumor types, group these
mutations into families, and develop a single small molecule therapy in a
tumor-agnostic manner that targets a specific family of mutations, termed a
MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and
Elizabeth Buck, Ph.D. For more information, please
visit www.blackdiamondtherapeutics.com.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/b8da4d92-789b-4f0a-a1e2-2739af370155)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.